Rutgers & Posch represented NASDAQ listed uniQure N.V. in a public offering of 6,736,841 ordinary shares at a price of $47.50 per share, as well as pre-funded warrants to purchase 526,316 of its ordinary shares to certain investors. The gross proceeds to the company were approximately $345 million.
uniQure is advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.
Bas Visée and Jamie Pellegrom advised advised uniQure. Rutgers & Posch teamed up with US firm Morgan Lewis.
For more information read uniQure’s announcements.